MedDataX Logo

Study With Rupatadine in Mosquito-Bite Allergic Adult Subjects

NCT ID: NCT00258141

Last Updated: 2005-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will find out how effective rupatadine is in the treatment of mosquito bite symptoms in adult patients allergic to mosquito bites.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Mosquito-bite symptoms include wheals and pruritic bite papules. Oral antihistamines have shown to decrease whealing ang accompanying pruritus in placebo-controlled trials.

Subjects will be treated for 4 days, and exposed to experimental mosquito bite at day 3.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allergy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rupatadine

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Recent history of suffering from mosquito-bite reactions.
* At least 5 mm diameter mosquito-bite wheal from Aedes aegypti laboratory mosquitoes

Exclusion Criteria

* Pregnancy or lactating females
* Oral antihistamines, corticosteroids or non-steroid anti-inflammatory drugs (NSAID) use within two weeks before the study.
* Severe or moderate systemic illness
* Allergy to rupatadine or other antihistamines
* Anaphylaxis from mosquito bites
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

J. Uriach and Company

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Timo Reunala, Prof.

Role: PRINCIPAL_INVESTIGATOR

Medical School, University of Tampere and Tampere University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ulappatorin Lääkäriasema

Espoo, , Finland

Site Status

Koskiklinikka, Tampere Lääkärikeskus

Tampere, , Finland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Finland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Timo Reunala, Prof.

Role: CONTACT

Phone: (+358) 331165167

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DM03RUP/IV/05

Identifier Type: -

Identifier Source: org_study_id